Literature DB >> 2217189

Purification and characterization of recombinant Rev protein of human immunodeficiency virus type 1.

C M Nalin1, R D Purcell, D Antelman, D Mueller, L Tomchak, B Wegrzynski, E McCarney, V Toome, R Kramer, M C Hsu.   

Abstract

Recombinant Rev protein of human immunodeficiency virus type 1 has been expressed in Escherichia coli and purified by ion-exchange and gel-filtration chromatography. Specific binding of the purified protein to the Rev-responsive element of the viral RNA is demonstrated. Physical characterization of the purified protein by circular dichroism and intrinsic fluorescence spectroscopy indicate that the protein preparation is suitable for structural analysis. Circular dichroism measurements show that the protein is approximately 40-45% alpha-helix. Tryptophan fluorescence measurements suggest that the single tryptophan residue is located near the surface of the protein. Gel-filtration chromatography of the protein indicates that it has an apparent molecular mass of 33,000 daltons. This suggests that the protein in solution forms a stable tetramer consisting of monomers having molecular mass of 13,000 daltons.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2217189      PMCID: PMC54794          DOI: 10.1073/pnas.87.19.7593

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  A second post-transcriptional trans-activator gene required for HTLV-III replication.

Authors:  J Sodroski; W C Goh; C Rosen; A Dayton; E Terwilliger; W Haseltine
Journal:  Nature       Date:  1986 May 22-28       Impact factor: 49.962

2.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA.

Authors:  M B Feinberg; R F Jarrett; A Aldovini; R C Gallo; F Wong-Staal
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

3.  Determination of enzymatic activity in polyacrylamide gels. I. Enzymes catalyzing the conversion of nonreducing substrates to reducing products.

Authors:  O Gabriel; S F Wang
Journal:  Anal Biochem       Date:  1969-03       Impact factor: 3.365

4.  Secondary structure is the major determinant for interaction of HIV rev protein with RNA.

Authors:  H S Olsen; P Nelbock; A W Cochrane; C A Rosen
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

Review 5.  The histones.

Authors:  R Sperling; E J Wachtel
Journal:  Adv Protein Chem       Date:  1981

6.  Exposure of tryptophanyl residues in proteins. Quantitative determination by fluorescence quenching studies.

Authors:  M R Eftink; C A Ghiron
Journal:  Biochemistry       Date:  1976-02-10       Impact factor: 3.162

7.  Expression of the art/trs protein of HIV and study of its role in viral envelope synthesis.

Authors:  D M Knight; F A Flomerfelt; J Ghrayeb
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

8.  Eucaryotic initiation factor 4B of wheat germ binds to the translation initiation region of a messenger ribonucleic acid.

Authors:  J S Butler; J M Clark
Journal:  Biochemistry       Date:  1984-02-28       Impact factor: 3.162

9.  beta-Endorphin. Circular dichroism of synthetic human analogs with various chain lengths in methanol solutions.

Authors:  M D Jibson; C H Li
Journal:  Int J Pept Protein Res       Date:  1981-09

10.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Authors:  S K Arya; C Guo; S F Josephs; F Wong-Staal
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

View more
  14 in total

1.  Human immunodeficiency virus type 1 Rev activation can be achieved without Rev-responsive element RNA if Rev is directed to the target as a Rev/MS2 fusion protein which tethers the MS2 operator RNA.

Authors:  S Venkatesan; S M Gerstberger; H Park; S M Holland; Y Nam
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes.

Authors:  T J Hope; N P Klein; M E Elder; T G Parslow
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  Inhibition of human immunodeficiency virus type 1 Rev-Rev-response element complex formation by complementary oligonucleotides.

Authors:  D J Chin
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif.

Authors:  M L Zapp; T J Hope; T G Parslow; M R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

5.  Extensive sequence-specific information throughout the CAR/RRE, the target sequence of the human immunodeficiency virus type 1 Rev protein.

Authors:  E T Dayton; D A Konings; D M Powell; B A Shapiro; L Butini; J V Maizel; A I Dayton
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

6.  Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element.

Authors:  J Kjems; M Brown; D D Chang; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

7.  Rapid and efficient purification of RNA-binding proteins: application to HIV-1 Rev.

Authors:  Marco Marenchino; David W Armbruster; Mirko Hennig
Journal:  Protein Expr Purif       Date:  2008-09-25       Impact factor: 1.650

8.  Characterization of human immunodeficiency virus-1 (HIV-1) rev by (time-resolved) fluorescence spectroscopy.

Authors:  A J Kungl; C Seidel; A Schilk; T J Daly; H F Kauffmann; M Auer
Journal:  J Fluoresc       Date:  1994-12       Impact factor: 2.217

9.  Dominant negative mutants of human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo.

Authors:  H Bogerd; W C Greene
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 regulator of virion expression, rev, forms nucleoprotein filaments after binding to a purine-rich "bubble" located within the rev-responsive region of viral mRNAs.

Authors:  S Heaphy; J T Finch; M J Gait; J Karn; M Singh
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.